Hospitals and drugmakers clash in court over the revived 340B rebate pilot
Hospital suit filed Oct 9, 2026; drugmaker motions Oct 14; opposition filed Oct 21; pilot scheduled to start Jan 1, 2027
From Briefing for the week of October 20 – October 26, 2026
What changed
The American Hospital Association, the Maine Hospital Association and four safety-net hospitals sued in the U.S. District Court for the District of Maine on Oct. 9 to stop the administration's revised 340B rebate model, which is scheduled to take effect Jan. 1, 2027. Under a rebate model, covered hospitals buy certain drugs at full price and later claim a rebate rather than receiving the discount at purchase. Per Healthcare Dive, AbbVie, Bristol-Myers Squibb and Boehringer Ingelheim moved to intervene on Oct. 14, and PhRMA filed separately. On Oct. 21 the AHA and co-plaintiffs asked the court to deny intervention, noting that a court rejected similar requests in the earlier case over the first version of the pilot. The plaintiffs say the program would impose over $1 billion a year in administrative costs on hospitals.
Why it matters
340B is meant to help safety-net providers stretch limited resources, and the dispute is about who bears cash-flow and administrative burden. Drugmakers argue rebates would curb duplicate discounts; hospitals argue the model threatens safety-net finances. The $1 billion estimate is the plaintiffs' own and is not independently verified. No ruling has been reported.
Sources
- AHA News: AHA urges court to reject drug industry intervention in 340B rebate program case (Oct. 21, 2026) (advocacy source: hospital trade association, a party to the case) (secondary)
- Healthcare Dive: Drugmakers seek to intervene in lawsuit challenging 340B pilot (Oct. 19, 2026) (secondary)
- Federal Register: Notice Regarding 340B Rebate Model Pilot Program (Aug. 3, 2026) (primary)